Zepbound is a dual GIP and GLP-1 receptor agonist approved for obesity treatment
These agents have the potential to improve treatment outcomes, lower cardiometabolic risk, and enhance functional recovery by addressing both the metabolic and psychiatric components of illness [21,42,62]
In this article, Ill unpack what CMS originally planned to do, what these GLP-1s are currently approved for, and how the reversal impacts patients, physicians, and the broader health system
Online Convenience : Everything is done online, from consultations to prescription refills, so you can focus on your health without extra stress
HRT and how it can help with weight loss Hormone replacement therapy involves adding back estrogen, and often progesterone, to replace the hormones the ovaries no longer produce after menopause